Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease.

Abstract

OBJECTIVES:

Blood monocytes are the precursors of the lipid-laden foam cells that are the hallmark of early atherosclerotic lesions, and monocyte chemoattractant protein-1 (MCP-1) plays important roles in their recruitment to the vessel wall. In this study, we measured serum levels of MCP-1 in patients with peripheral arterial obstructive disease (PAOD) and investigated whether intravenous prostaglandin E1 (PGE1) treatment, which produces clinical benefits in PAOD, might decrease such levels.

METHODS:

Eight patients with PAOD at Fontaine stage II to IV were treated with a daily intravenous infusion of 10 microg of PGE1 for 7 consecutive days. Blood samples before and after 7-day PGE1 treatment were used for assays of MCP-1, interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), von Willebrand factor (vWF), and endothelin-1 (ET-1).

RESULTS:

Serum MCP-1 levels in patients with PAOD were significantly higher than those in healthy control subjects (263.8 +/- 52.8 vs 136.5 +/- 15.0 pg/mL, P =.002). PGE1 administration for 7 days resulted in a significant decrease in the MCP-1 level, from 263.8 +/- 52.8 to 196.1 +/- 25.5 pg/mL (P =.02), whereas levels of IL-6, hs-CRP, and ET-1 and the activity of vWF were not affected.

CONCLUSIONS:

Serum MCP-1 levels were elevated in patients with PAOD, indicating the involvement of activation of monocytes in the pathogenesis of this disorder. Parenteral administration of PGE1 appeared to decrease circulating MCP-1 levels, which might lead to the suppression of the development of atherosclerotic lesions in patients with PAOD.

• Authors: Keiji Matsui, Uichi Ikeda, Yoshiaki Murakami, Toru Yoshioka, Kazuyuki Shimada
• Journal: American heart journal (Am Heart J) Vol. 145 Issue 2 Pg. 330-3 (Feb 2003) ISSN: 1097-6744 [Electronic] United States
• PMID: 12595852 (Publication Type: Journal Article)

Chemical References

• Biomarkers
• Chemokine CCL2
• Endothelin-1
• Fibrinolytic Agents
• Interleukin-6
• Vasodilator Agents
• von Willebrand Factor
• C-Reactive Protein
• Alprostadil

Topics

• Adult
• Aged
• Alprostadil (administration & dosage, therapeutic use)
• Arterial Occlusive Diseases (blood, drug therapy)
• Biomarkers (blood)
• C-Reactive Protein (analysis)
• Case-Control Studies
• Chemokine CCL2 (blood)
• Endothelin-1 (blood)
• Female
• Fibrinolytic Agents (administration & dosage, therapeutic use)
• Humans
• Injections, Intravenous
• Interleukin-6 (blood)
• Intermittent Claudication (blood, drug therapy)
• Male
• Middle Aged
• Peripheral Vascular Diseases (blood, drug therapy)
• Vasodilator Agents (administration & dosage, therapeutic use)
• von Willebrand Factor (analysis)